ASHA-091 demonstrates efficacy in Parkinson’s Disease

Asha Therapeutics' lead mitochondrial dynamics targeting drug ASHA-091 demonstrates robust efficacy and safety in preclinical murine models.

Data emerging from an ongoing preclinical study using Asha Therapeutics' mitochondrial fragmentation inhibitor ASHA-091 is demonstrating robust preclinical efficacy and safety in mice. Scientists administered a conservative dosing regime of ASHA-091 in mice with Parkinson's Disease pathology. Acute treatment led to marked reversal of motor impairment.